featured
Isatuximab + Pomalidomide + Dexamethasone vs Pomalidomide + Dexamethasone for Relapsed and Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Lancet Oncol 2022 Feb 10;[EPub Ahead of Print], PG Richardson, A Perrot, J San-Miguel, M Beksac, I Spicka, X Leleu, F Schjesvold, P Moreau, MA Dimopoulos, JS Huang, J Minarik, M Cavo, HM Prince, L Malinge, F Dubin, H van de Velde, KC AndersonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.